Haitao Ma

Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial

Jianxing He, Chunxia Su, Wenhua Liang et al. · The Lancet Respiratory Medicine · 2021 · 184 citations

Medicine, Oncology, Pharmacology +13

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

Si‐Yang Liu, Hua Bao, Qun Wang et al. · Nature Communications · 2021 · 75 citations · Full text

Medicine, Molecular Genetics, Oncology +15

The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)

Junjie Xi, Wen‐Zhao Zhong, Weimin Mao et al. · Journal of Thoracic Oncology · 2018 · 73 citations

Pharmacy, Pharmacotherapy, Precision Oncology +11

Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study

Xue‐Ning Yang, Hong‐Hong Yan, Jun Wang et al. · JTO Clinical and Research Reports · 2021 · 35 citations · Full text

Medicine, Oncology, Surgery +17

Prognostic role of preoperative platelet, fibrinogen, and D‐dimer levels in patients with non‐small cell lung cancer: A multicenter prospective study

Can Hou, Feng Jiang, Haitao Ma et al. · Thoracic Cancer · 2019 · 34 citations · Full text

Medicine, Oncology, Pulmonology +14